You are currently viewing a new version of our website. To view the old version click .
Journal of Personalized Medicine
  • Review
  • Open Access

14 March 2025

Exploring the Immunological Role of the Microbial Composition of the Appendix and the Associated Risks of Appendectomies

,
,
,
,
,
and
1
Department of Microbiology, Noakhali Science and Technology University, Noakhali 3814, Bangladesh
2
Department of Microbiology, Jagannath University, Dhaka 1100, Bangladesh
3
Department of Pharmacy, Noakhali Science and Technology University, Noakhali 3814, Bangladesh
4
Department of Biotechnology, Yeungnam University, Gyeongsan, 38541, Republic of Korea
This article belongs to the Special Issue Gut Microbiome and Its Impact on Human Health

Abstract

The appendix, an integral part of the large intestine, may serve two purposes. First of all, it is a concentration of lymphoid tissue that resembles Peyer’s patches. It is also the main location in the body for the creation of immunoglobulin A (IgA), which is essential for controlling intestinal flora’s density and quality. Second, the appendix constitutes a special place for commensal bacteria in the body because of its location and form. Inflammation of the appendix, brought on by a variety of infectious agents, including bacteria, viruses, or parasites, is known as appendicitis. According to a number of studies, the consequences of appendectomies may be more subtle, and may relate to the emergence of heart disease, inflammatory bowel disease (IBD), and Parkinson’s disease (PD), among other unexpected illnesses. A poorer prognosis for recurrent Clostridium difficile infection is also predicted by the absence of an appendix. Appendectomies result in gut dysbiosis, which consequently causes different disease outcomes. In this review, we compared the compositional differences between the appendix and gut microbiome, the immunological role of appendix and appendix microbiome (AM), and discussed how appendectomy is linked to different disease consequences.

1. Introduction

The human appendix, an anatomical structure characterized by its slender, tubular projection from the cecum situated in the lower right quadrant of the abdomen, has remained a focal point of scientific inquiry [1]. Frequently categorized as a trivial organ, the appendix continues to captivate scientific interest due to its intriguing presence within human anatomy [1,2]. Morphologically, the appendix typically measures approximately 9 cm in length, exhibiting variations ranging from 5 to 35 cm, with a diameter averaging around 6 mm [2,3].
The anatomical positioning of the appendix is notably variable, impacting both diagnostic procedures and surgical intervention. The most common anatomical orientation of the appendix is retrocecal, located posterior to the cecum, accounting for approximately 65–70% of all cases. Alternatively, in about 25–30% of individuals, the appendix descends into the pelvic region, known as the pelvic position. Less frequently, the appendix may adopt other positions such as pre- or post-ileal (5%), subcecal, paracaecal (alongside the cecum), or near the sacral promontory [4,5,6,7]. These positional variations can influence the clinical presentation and diagnosis of appendicitis, as the location of pain may differ depending on the appendix’s position within the abdominal cavity [7].
The evolutionary history of the appendix is fascinating and complex. Initially deemed an imperceptible organ with no apparent function, the appendix was thought to be a remnant of a larger cecal structure that aided in the digestion of cellulose when our ancestors had a more herbivorous diet [8,9]. However, this view has shifted dramatically in recent years. Research suggests that the appendix has grown autonomously in several mammalian lineages, indicating that it may serve an important purpose [1,2,8,10]. It appears that the appendix has been part of mammalian anatomy for at least 80 million years, much longer than Darwin’s theory would suggest [1]. This longevity across evolutionary history implies that the appendix may have conferred a selective advantage.
Emerging theories propose that the appendix’s microbiome and its interaction with the gut microbiome are crucial for maintaining a balanced immune response. One of the leading theories today is that the appendix acts as a reservoir for commensal bacteria (probiotics), playing a crucial role in repopulating the gut microbiome (GM) after episodes of gastrointestinal (GI) disease [11,12]. This function is supported by the existence of a dense concentration of lymphoid tissue within the appendix, which suggests an immunological role. This “backup” system underscores the appendix’s significance in gut health, suggesting that while we can live without it, its presence may offer subtle yet important benefits [11,12]. This lymphatic tissue can encourage the growth of useful gut bacteria and play a part in the body’s immune response. The appendix’s association with the immune system is further supported by its role in the development of B and T lymphocytes and the production of IgA antibodies. These functions are particularly active during the first few years of life, indicating that the appendix may play a role in the development of the immune system in young individuals [2,13,14].
Despite these findings, the exact function of the appendix remains a topic of debate. Some scientists argue that if the appendix were truly vital, its removal would result in more significant health consequences [14,15,16]. However, the lack of observable health problems following an appendectomy does not necessarily mean the appendix is useless; it may indicate that other parts of the body can compensate for its absence [15,16]. The appendix is an integral part of the immune system with a significant role in maintaining gut health. Its evolutionary persistence suggests that it provides a beneficial function, possibly related to the GM and immune responses [2,9,10]. As research continues, our understanding of the appendix’s role in human physiology will likely become clearer, potentially leading to new insights into its contribution to our overall health and well-being.

2. Appendix Microbiome Composition in a Healthy Person

Studies investigating the microbial composition of the human appendix have revealed a rich and diverse ecosystem predominantly comprising four major phyla: Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria [17,18]. This microbial consortium exhibits dynamic interactions, forming intricate networks that influence various aspects of host physiology, including nutrient metabolism, immune modulation, and pathogen resistance [12,19,20].
Firmicutes are often the most abundant phylum within the AM. They are known for their role in fermenting indigestible carbohydrates, producing short-chain fatty acids (SCFAs) such as butyrate, propionate, and acetate [21,22]. Bacterial genera of this phylum include Ruminiococcus, Clostridium, and Lactobacillus [23]. These SCFAs serve as a primary energy source for colonocytes and exhibit anti-inflammatory properties, which are vital for maintaining intestinal barrier integrity and preventing the invasion of pathogens [21,24]. Moreover, Firmicutes contribute to the regulation of the host’s immune system. They influence the balance of pro- and anti-inflammatory cytokines, which are key mediators in immune response [24]. This modulation is essential for maintaining gut homeostasis and can impact the development and progression of various infectious and inflammatory diseases [24]. The Firmicutes/Bacteroidetes ratio is also a significant marker of gut health, changing throughout different life stages and reflecting the dynamic nature of the GM [25,26]. Firmicutes and Bacteroidetes account for 90% of human bacterial species [27]. Alterations in this ratio have been associated with various health conditions, including obesity and metabolic syndrome [28]. Firmicutes interact with the immune system by impacting the proliferation, growth, and differentiation of epithelial and immune cells [21,25]. This interaction is crucial for the proper functioning of the gut’s immune defense mechanisms. Both diversity and functionality in Firmicutes are essential for optimal gut health. Their ability to produce butyrate supports both immune regulation and the proper functioning of the intestinal lining, highlighting their importance in the overall health of the host [24,25,26,28].
Bacteroidetes are another significant group within the AM. Bacterial genera of this phylum include Bacteroides, Prevotella, and Porphyromonas, in which Bacteroides alone account for around 30% of all gut bacteria [27]. Bacteroidetes are renowned for their ability to degrade complex polysaccharides and proteins, facilitating digestion and nutrient absorption [12]. Their enzymatic machinery is specialized for breaking down dietary fibers, which are otherwise indigestible by human enzymes, thus playing a pivotal role in the host’s energy harvest [29]. Beyond digestion, Bacteroidetes are integral to gut health and immunity. They engage in colonization resistance, a process where they outcompete pathogenic bacteria for adhesion sites and nutrients, and produce bacteriocins to inhibit the growth of potential pathogens [30]. This competitive exclusion is crucial for maintaining a balanced GM and preventing infections. Moreover, Bacteroidetes influence the immune system by modulating the production of anti-inflammatory molecules and interacting with the gut’s mucosal immune system [31]. They help maintain the integrity of the intestinal epithelium, which serves as the first line of defense against external pathogens [32]. The mode of action of Bacteroidetes includes the stimulation of immune responses through the production of signaling molecules that can affect immune cell differentiation and function. This interaction is essential for the maturation of a strong immune system capable of responding to a variety of challenges [33,34].
Actinobacteria, while less abundant in the AM compared to Firmicutes and Bacteroidetes, play a significant role in human health [35]. Bacterial genera of this phylum include both anaerobic and aerobic bacterial including Bifidobacteria, Propionibacteria, Corynebacteria, Streptomyces, Nocardia, Micromonospora, Actinoplanes, and Streptosporangium, of which Bifidobacteria are most common in the human gut [36]. They are adept at degrading complex sugars, which is crucial for the digestion of dietary fibers that human enzymes cannot process. This degradation process results in the production of bioactive compounds, including various vitamins and anti-inflammatory substances [37]. Bifidobacteria, a well-known genus within the Actinobacteria phylum, are widely recognized as probiotics. They contribute to gut health by enhancing the intestinal barrier, modulating the immune system, and producing lactic acid, which lowers the pH of the gut environment, inhibiting harmful bacteria [38]. Furthermore, Bifidobacteria can synthesize essential vitamins such as biotin, folate, and vitamin K, which are vital for the host’s metabolism [35,39]. The mode of action of Actinobacteria involves not only the breakdown of complex carbohydrates but also the interaction with the host’s immune cells. They can influence the maturation and function of immune cells, thereby playing a role in both innate and adaptive immunity. This interaction is particularly important for the development of immune tolerance and the prevention of inflammatory diseases [40]. Recent studies have also highlighted the role of Actinobacteria in aging, showing that their abundance and diversity can change with age, impacting the overall health of the individual [37].
Proteobacteria are a major group (phylum) of bacteria that includes different pathogens, for instance, Brucella, Rickettsia, Bordetella, Neisseria, Escherichia, Salmonella, Vibrio, and Helicobacter [32,41]. Proteobacteria form a minor portion [42]. Desulfovibrio, Escherichia, Klebsiella, and Shigella are the major representative Proteobacteria in the intestinal microbiota. They form a minor portion of the GM, and are most unstable [43]. While some members are opportunistic pathogens, many non-pathogenic Proteobacteria are beneficial, contributing to microbial diversity and performing essential metabolic functions [44]. These beneficial Proteobacteria are involved in nitrogen fixation, an important process for recycling nitrogen within the gut ecosystem [45]. They also participate in the breakdown of complex molecules, which can contribute to nutrient cycling and energy production within the gut [37,44]. Moreover, Proteobacteria can influence the immune system. They are involved in the production of molecules like lipopolysaccharides, which can modulate immune responses. Some Proteobacteria are known to stimulate the production of anti-inflammatory cytokines, helping to maintain a balanced immune response and protect against inflammatory diseases [46]. The mode of action of Proteobacteria in the gut includes their interaction with other microbes and the host’s immune cells. They can compete with pathogenic bacteria, preventing their overgrowth and colonization. This competitive interaction is crucial for maintaining a healthy GM and preventing infections [47].
Overall, the AM in a healthy person is a complex and dynamic community that plays a significant role in gut health and the immune system. The four major phyla, Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria, contribute to the functionality of the GM, with implications for the gut–brain axis and overall well-being. Understanding the composition and function of the AM is vital for the development of strategies to maintain gut health and prevent diseases related to microbial imbalances.

3. Appendix Versus Gut Microbiome

The human appendix and gut are both integral components of the digestive system, each with distinct roles and characteristics. However, there are some differences between AM and GM that are discussed in more detail below (Table 1).
Table 1. Differences between appendix and gut microbiome.
One of the key differences between the appendix and the GM is the formation of biofilms. In the appendix, biofilms are robust and play a crucial role in protecting and preserving the microbiome [55]. In the gut, biofilms also exist but are typically less dense and more susceptible to disruption. When the GM is depleted, the appendix can release bacteria from its biofilms to repopulate the gut, thus maintaining a healthy microbial balance [56].

4. Immunological Function of Appendix and Appendix Microbiome

4.1. Immunological Roles

The appendix is rich in lymphoid tissue, which plays an immunological function. Lymphoid tissue plays a crucial role in promoting the growth of beneficial gut bacteria (i.e., Blautia sp., Enterococcus hirae, Lachnospiraceae bacterium, Collinsella aerofaciens) (Figure 1) [52]. The appendix provides a protected environment for these beneficial bacteria [52]. Within the appendix, lymphoid tissue forms a network of structures called follicles, which contain immune cells like B and T lymphocytes [57]. These immune cells are essential for the immune response but appear to be more tolerant towards beneficial bacteria in the appendix than in the main gut. This tolerance allows beneficial bacteria to reside and potentially replicate within the appendix, acting as a reservoir [52].
Figure 1. A schematic diagram representing the difference between the appendix and colon layers. The figure shows that the appendix has more abundant and pronounced lymphoid follicles and a different microbiome composition compared to the colon.
Furthermore, the appendix might play a role in “educating” the immune system to distinguish between beneficial and harmful bacteria [2]. By encountering diverse bacterial populations within the appendix, the immune system can learn to tolerate beneficial bacteria while remaining vigilant against pathogens [10]. This training of the immune system is thought to contribute to developing lenience, precluding the immune system from exaggerating to harmless elements, which can lead to allergies and auto-immune diseases (ADs) [58,59,60].

4.2. Interaction with Immune System

The appendix, on the other hand, interacts with the host’s immune system mainly by gut-associated lymphoid tissue (GALT), a network of immune cells concentrated in the appendix and other intestinal tissues which comprise different immune cells like dendritic cells (DCs), macrophages, and innate lymphocytes that serves as the first line defense (Figure 1) [17,56,61]. Specific commensal bacteria like Bifidobacteria within the appendix can stimulate the development and function of GALT [62]. Moreover, Bifidobacteria are associated with oncogene suppression and immune modulation [63,64]. B. longum may suppress azoxymethane-induced colon tumors by decreasing colonic mucosal proliferation and ornithine decarboxylase and ras-p21 activity [64]. They may help decrease the activity of different pro-carcinogenic enzymes such as β-glucosidase and β-glucuronidase [63]. B. bifidum was reported to decrease the activity of β-glucosidase [63], and B. longum lowered the activity of β-glucosidase and β-glucuronidase [65]. This highlights the potential role of the AM in both gut homeostasis (stable internal environment) and disease pathogenesis (disease development) mediated by microbes and the immune system [13,66]. Studies using germ-free mice (mice raised in a sterile environment devoid of microbiota) demonstrate the critical role of gut bacteria in GALT development. Bifidobacterium pseudolongum, Lactobacillus johnsonii, and Olsenella significantly improved the efficiency of immune checkpoint inhibitors in four cancer mouse models. B. pseudolongum modified improved immunotherapy responses by way of inosine production [67]. This observation underscores the dependence of GALT on microbial stimulation for proper development and function in animals [56,68].
There are several ways in which AM can interact with the immune system. Certain bacterial strains within the AM can promote the development of Tregs, a specialized subset of immune cells that suppress excessive immune responses and maintain tolerance to commensal bacteria. For instance, Lactobacillus rhamnosus stimulates the cell proliferation rate of bowel epithelial cells, enhances repairing of the mucosa damage caused by radiotherapy and/or chemotherapy, helps maintain bacterial equilibrium within the bowel, and inhibits bacterial translocation into the tissues [69,70,71]. This helps prevent autoimmune reactions against the body’s own tissues [72,73]. In response to Lactobacillus, epithelial cells increase the extracellular expression of MUC3 mucin which limits the adhesion of pathogens like enteropathogen E coli E2348/69 [70]. A similar result was reported with Lactobacillus casei GG which reduces the adhesion of E. coli C25 in epithelial cells [69]. The appendix’s lymphoid tissue provides a niche for the maturation of B and T lymphocytes, the key players in the adaptive immune response. These immune cells learn to recognize and respond to foreign antigens (substances that trigger an immune response) while remaining tolerant to self-antigens [74]. The appendix epithelium produces significant amounts of IgA, a type of antibody that neutralizes pathogens on mucosal surfaces (surfaces like the lining of the gut) and prevents them from adhering and causing infection (Figure 2) [75]. This localized immune response within the appendix complements the broader immune activities of the gut. Defects in IgA production cause increases in specific bacterial taxa like Bacteroides in the progression of colitis [76]. These findings are also supported by recent studies. In one recent study, the association of appendectomies with an increased risk of colitis-associated cancer (CAC) was examined using five-week-aged male BALB/c mice. The results showed that UC patients with a previous appendectomy had decreased intratumor CD3+ and CD8+ T-cell densities compared with UC patients without a previous appendectomy [77].
Figure 2. Immunological function of the appendix. Lymphoid tissue of the appendix forms a GALT (gut-associated lymphoid tissue) network using macrophages, neutrophils, dendritic cells, and T cells. Moreover, lymphoid cells and Treg cells help to educate the immune system to counter the pathogens upon infection.
Studies suggest that an altered microbial composition may trigger an inappropriate immune response against commensal bacteria, leading to intestinal tissue damage [78]. Manipulating the AM can promote the development of regulatory T cells (Tregs) and suppress autoimmune reactions [79,80]. Additionally, they can enhance immune responses against pathogens and aid in restoring balance to the GM following antibiotic use or infections [17,81].

6. Microbe-Based Therapies

Appendectomy leads to gut dysbiosis, resulting in IBDs, neurological disorders, ADs, and so on. Different methods aiming to adjust the gut microbial composition and restore dysbiosis have been explored as a means of managing the clinical conditions caused by gut dysbiosis. Examples of such methods include probiotics, prebiotics, postbiotics, symbiotics, fecal microbiota transplantation (FMT), phage-based therapeutics, and engineered microbes [202].
Probiotics are good bacteria and yeast that are beneficial to the health. Prebiotics are high-fiber foods that help the growth of beneficial intestinal microbes. Postbiotics are beneficial metabolites or byproducts produced by gut microbes that have various beneficial health impacts [202]. The use of prebiotics, probiotics, and postbiotics is of great interest to the scientific community for the treatment of complications associated with gut dysbiosis (Table 7). Extensive use of antibiotics causes gut microbial dysbiosis and the emergence of multidrug-resistant pathogens [203,204,205]. The use of antibiotics during pregnancy may also impact the GM of infants, resulting in different GM-associated complications. A recent study showed that prebiotics in mothers could be an amazing alternative for reducing the disease severity in infants [206]. The use of multi-strain probiotics is one of the most-used microbe-based methods in clinical trials, which has a great impact on the functional diversity of the gut microbiota during pregnancy, reducing obesity and gastrointestinal complications in CRC patients, overcoming skin inflammation, and improving neurological disorders [206,207,208,209,210] (Table 7).
FMT has garnered a lot of interest and investigation lately as a dysbiosis remedy, and different disease management strategies. FMT directly affects the gut microbiota by transferring the complete intestinal microbiota from a healthy donor to the recipient in the form of feces using colonoscopy, enema, nasogastric (NG) tube, or capsule form [211,212,213]. Recent clinical trials showed that L. acidophilus transplanted by FMT reduced the cholesterol level in patients by inhibiting hepatic Cholesterol 7α-hydroxylase, restoring ileum Fibroblast growth factor 15 and small heterodimer partner proteins [214]. FMT of the mixed microbial population helped to reduce insulin resistance and interrupted CDI recurrence in the recipients [211,212].
Table 7. Microbe-based therapies under clinical trial to treat diseases caused by gut dysbiosis.
Table 7. Microbe-based therapies under clinical trial to treat diseases caused by gut dysbiosis.
Therapy MethodUsed MicrobesDisease FocusKey FindingsReferences
Multi-strain probioticsStreptococcus thermophilus NCIMB 30438, B. breve NCIMB 30441, B. lactis NCIMB 30435, B. lactis NCIMB 30436, L. acidophilus NCIMB 30442, L. plantarum NCIMB 30437, L. paracasei NCIMB 30439, and L. helveticus NCIMB 30440ObesityPregnant women treated with multi-strain probiotics gave birth to a child who had decreased obesity-associated genera, Collinsella. Vaginally delivered infants had an increased number of Bifidobacterium and Bacteroides, and a decreased number of Enterococcus compared to the control group.[206]
Multi-strain probioticsL. rhamnosus (CECT 30031) and the cyanobacterium Arthrospira platensis (BEA_IDA_0074B)Skin inflammationOf the patients using the Global Acne Grading System, 17/40 (42.50%) were in the probiotic group (p  =  0.02), indicating that the probiotic used in this study was effective and well accepted.[208]
FMTL. acidophilusCholesterol levelInhibited hepatic Cholesterol 7α-hydroxylase, restored ileum Fibroblast growth factor 15, and small heterodimer partner.[214]
ProbioticsLiver functionL. acidophilus supplementation promoted the recovery of liver function.
Multi-strain probioticsB. longum, L. delbrueckii bulgaricus, and S. thermophilusImpact of probiotics on the functional diversity of the gut microbiota during pregnancySignificantly increased the genera Blautia Ruminococcus, and Subdoligranulum (p < 0.05). The functional genes of the gut microbiota involved in ABC transporters, oxidative phosphorylation, folate biosynthesis, and biotin metabolism were significantly increased in subjects receiving the probiotics (p < 0.05).[207]
ProbioticsB. longum CECT 7347 (ES1)Irritable bowel syndromeResponder rates, stool consistency, abdominal pain severity, and anxiety, when compared to placebo over an 84 d time period.[215]
PostbioticsHeat-treated B. longum CECT 7347 (HT-ES1)
ProbioticsB. longum NCC3001Irritable bowel syndrome (IBS)Improvements in anxiety and depression scores and a decrease in amygdala activation were observed. Moreover, the levels of butyric acid, tryptophan, N-acetyl tryptophan, glycine-conjugated bile acids, and free fatty acids were increased.[210]
ProbioticsB. breve M-16 VHuman modeB. breve M-16 V improved mood and sleep scores, decreased the heart rate under stress, and increased levels of pipecolic acid in stool samples, and improved mood and sleep scores in participants with high anxiety levels.[216]
ProbioticsLacticaseibacillus rhamnosus LRa05Helicobacter pylori eradicationDid not improve H. pylori eradication significantly, but improved liver activity and reduced the levels of inflammatory markers like IL-6 and TNF-α.[217]
Multi-strain probioticsB. infants, L. acidophilus, E. faecalis, and Bacillus cereusGastrointestinal complications in CRC patientsIncreased levels of Bifidobacterium, Streptococcus, and Blautia. Significantly Increased levels of SCFAs, mainly increasing acetate, butyrate, and propionate (p < 0.0001).[209]
FMTMixed microbial populationObesitySignificantly altered recipients’ phage and general microbial composition, suggesting that phages play an important role in changing the gut environment and thereby obesity.[218]
Capsulized FMTMixed microbial populationUCRemission induced in patients with UC by increasing the levels of Alistipes sp. and Odoribacter splanchnicus, and due to increased levels of indolelactic acid. Subjects without remission exhibited increased levels of E. coli and Klebsiella, and higher levels of 12,13-dihydroxy-9Z-octadecenoic acid and lipopolysaccharides.[213]
FMTMixed microbial populationInsulin resistanceFMT with or without metformin significantly improved insulin resistance, body mass index, and gut microbial compositions of type 2 diabetes patients[212]
FMTMixed microbial populationCDIRecurrent CDI patients with sustained resolution after FMT had increased levels of Ruminococcaceae and Lachnospiraceae, and depletion of Enterobacteriaceae[211]
Engineered bacteriaE. coli Nissle 1917 (EcN)CRCOral administration of EcN as a probiotic increased their presence in the tumor cell the level of salicylate in the urine of adenoma-bearing mice was increased indicating that EcN could be used to treat CRC.[219]
There have been conflicting outcomes where probiotics, prebiotics, postbiotics, and FMT are used. For example, some probiotic strains have been shown to help manage UC in certain randomized controlled studies, while CD has not consistently shown the same advantages [202]. It is difficult to draw firm conclusions on the efficacy of probiotics due to the wide variation in study designs, probiotic strains, doses, and patient demographics. Additionally, several studies have shown that FMT is useful in treating IBDs; however, the degree of success varies greatly. Furthermore, there is a continuous discussion about the long-term consequences and safety of microbiome manipulation, particularly when using aggressive techniques like FMT [220]. The possibility of spreading harmful bacteria as well as the long-term effects on the recipient’s immune system and metabolic functions are causes for concern.

7. Conclusions

Most of the research conducted on the impact of appendectomies on different disease outcomes involves statistical analysis, and there are very few experimental data on this topic. Moreover, much of the data found in this statistical research contradicts the experimental data found on the same topic. That is why more experimental data on the impact of appendectomies on different disease outcomes should be conducted. There are very few studies on the impact of appendectomies on neurological disorders (NDs) like depression, schizophrenia, PD, Amyotrophic lateral sclerosis (ALS), autism spectrum disorder (ASD), epilepsy, and migraines. More clinical and research data on these areas are desperately needed. Appendectomies are associated with some disease outcomes, but with different severities. Appendectomies are also linked to IBDs, but their impact on CD differs from UC. That is why it can be concluded that the association of appendectomies with different disease consequences is not uniform. Most of the disease consequences of appendectomies are caused by gut dysbiosis.

Author Contributions

Conceptualization, T.I., D. and M.A.H.; Data curation, T.I., M.S.S., N.T.T., D. and M.K.I.B.; Formal analysis, T.I. and D.; Funding acquisition, M.A.H. and M.L.; Investigation, M.S.S., N.T.T., M.K.I.B., M.A.H. and M.L.; Methodology, T.I., M.S.S., N.T.T., M.K.I.B., D., M.A.H. and M.L.; Project administration, M.A.H. and M.L.; Software, T.I. and D.; Resources, T.I., D., M.A.H. and M.L.; Supervision, M.A.H.; Validation, M.S.S., N.T.T., M.K.I.B., M.A.H. and M.L.; Visualization, T.I. and M.S.S., N.T.T. and M.K.I.B.; Writing—original draft, T.I. and D.; Writing—review and editing, T.I., M.S.S., N.T.T., M.K.I.B., D., M.A.H. and M.L. All authors have read and agreed to the published version of the manuscript.

Funding

Open Access Funding by the University of Applied Sciences Technikum Wien.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

The dataset is available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Smith, H.F.; Fisher, R.E.; Everett, M.L.; Thomas, A.D.; Randal Bollinger, R.; Parker, W. Comparative anatomy and phylogenetic distribution of the mammalian cecal appendix. J. Evol. Biol. 2009, 22, 1984–1999. [Google Scholar] [CrossRef] [PubMed]
  2. Kooij, I.A.; Sahami, S.; Meijer, S.L.; Buskens, C.J.; te Velde, A.A. The immunology of the vermiform appendix: A review of the literature. Clin. Exp. Immunol. 2016, 186, 1–9. [Google Scholar] [CrossRef]
  3. Deshmukh, S.; Verde, F.; Johnson, P.T.; Fishman, E.K.; MacUra, K.J. Anatomical variants and pathologies of the vermix. Emerg. Radiol. 2014, 21, 543–552. [Google Scholar] [CrossRef] [PubMed]
  4. Fenwick, A.K.C.; Hartery, A. Appendicitis and beyond: A pictorial review of various appendiceal abnormalities. Emerg. Radiol. 2021, 28, 651–664. [Google Scholar] [CrossRef] [PubMed]
  5. Deepthi, C. Study of Various Positions of Appendix in Adult Human Cadavers. IOSR J. Dent. Med. Sci. 2022, 21, 1–3. [Google Scholar] [CrossRef]
  6. Sarma, M.; Dutta, M.; Doley, A. Different Positions of Vermiform Appendix in Human Cadavers: A Cross-sectional Study. Int. J. Anat. Radiol. Surg. 2022, 11, AO29–AO32. [Google Scholar] [CrossRef]
  7. Lokanayaki, V.; Lavanya devi, K. A study on various positions of vermiform appendix in adult human cadavers. Indian J. Clin. Anat. Physiol. 2019, 6, 61–64. [Google Scholar] [CrossRef]
  8. Smith, H.; Fisher, R.; Everett, M.L.; Thomas, A.; Bollinger, R.R. Evolution of the Human Appendix: A Biological “Remnant” No More. ScienceDaily 2009. Available online: https://www.sciencedaily.com/releases/2009/08/090820175901.htm (accessed on 3 November 2024).
  9. Smith, H.F.; Heather Smith, C.F. A review of the function and evolution of the cecal appendix. Anat. Rec. 2023, 306, 972–982. [Google Scholar] [CrossRef]
  10. Girard-Madoux, M.J.H.; Gomez de Agüero, M.; Ganal-Vonarburg, S.C.; Mooser, C.; Belz, G.T.; Macpherson, A.J.; Vivier, E. The immunological functions of the Appendix: An example of redundancy? Semin. Immunol. 2018, 36, 31–44. [Google Scholar] [CrossRef]
  11. Lee, M.S.; Sulit, A.; Frizelle, F.; Purcell, R. The microbiome in adult acute appendicitis. Gut Microbiome 2022, 3, e8. [Google Scholar] [CrossRef]
  12. Oh, S.J.; Pimentel, M.M.; Leite, G.G.S.; Celly, S.; Villanueva-Millan, M.J.; Lacsina, I.; Chuang, B.; Parodi, G.; Morales, W.; Weitsman, S.; et al. Acute appendicitis is associated with appendiceal microbiome changes including elevated Campylobacter jejuni levels. BMJ Open Gastroenterol. 2020, 7, e000412. [Google Scholar] [CrossRef]
  13. Petruzziello, C.; Saviano, A.; Ojetti, V. Probiotics, the Immune Response and Acute Appendicitis: A Review. Vaccines 2023, 11, 1170. [Google Scholar] [CrossRef]
  14. Lee, S.; Jang, E.J.; Jo, J.; Park, S.J.; Ryu, H.G. Long-term impacts of appendectomy associated with increased incidence of inflammatory bowel disease, infection, and colorectal cancer. Int. J. Colorectal. Dis. 2021, 36, 1643–1652. [Google Scholar] [CrossRef]
  15. Guan, L.; Liu, Z.; Pan, G.; Zhang, B.; Wu, Y.; Gan, T.; Ouyang, G. The global, regional, and national burden of appendicitis in 204 countries and territories, 1990–2019: A systematic analysis from the Global Burden of Disease Study 2019. BMC Gastroenterol. 2023, 23, 44. [Google Scholar] [CrossRef] [PubMed]
  16. Cunha, J.P. Does Removing the Appendix (Appendectomy) Affect Anything? EMedicineHealth 2020. Available online: https://www.emedicinehealth.com/does_removing_appendix_affect_anything/article_em.htm (accessed on 22 March 2024).
  17. Guinane, C.M.; Tadrous, A.; Fouhy, F.; Anthony Ryan, C.; Dempsey, E.M.; Murphy, B.; Andrews, E.; Cotter, P.D.; Stanton, C.; Paul Ross, R. Microbial composition of human appendices from patients following appendectomy. mBio 2013, 4, 1–6. [Google Scholar] [CrossRef]
  18. Reynoso-García, J.; Miranda-Santiago, A.E.; Meléndez-Vázquez, N.M.; Acosta-Pagán, K.; Sánchez-Rosado, M.; Díaz-Rivera, J.; Rosado-Quiñones, A.M.; Acevedo-Márquez, L.; Cruz-Roldán, L.; Tosado-Rodríguez, E.L.; et al. A complete guide to human microbiomes: Body niches, transmission, development, dysbiosis, and restoration. Front. Syst. Biol. 2022, 2, 951403. [Google Scholar] [CrossRef] [PubMed]
  19. Cai, S.; Fan, Y.; Zhang, B.; Lin, J.; Yang, X.; Liu, Y.; Liu, J.; Ren, J.; Xu, H. Appendectomy Is Associated with Alteration of Human Gut Bacterial and Fungal Communities. Front. Microbiol. 2021, 12, 724980. [Google Scholar] [CrossRef] [PubMed]
  20. Thomas, F.; Hehemann, J.H.; Rebuffet, E.; Czjzek, M.; Michel, G. Environmental and gut Bacteroidetes: The food connection. Front. Microbiol. 2011, 2, 9588. [Google Scholar] [CrossRef]
  21. Riva, A.; Borgo, F.; Lassandro, C.; Verduci, E.; Morace, G.; Borghi, E.; Berry, D. Pediatric obesity is associated with an altered gut microbiota and discordant shifts in F irmicutes populations. Environ. Microbiol. 2017, 19, 95–105. [Google Scholar] [CrossRef]
  22. Biddle, A.; Stewart, L.; Blanchard, J.; Leschine, S. Untangling the Genetic Basis of Fibrolytic Specialization by Lachnospiraceae and Ruminococcaceae in Diverse Gut Communities. Diversity 2013, 5, 627–640. [Google Scholar] [CrossRef]
  23. Davey, L.; Halperin, S.A.; Lee, S.F. Thiol-Disulfide Exchange in Gram-Positive Firmicutes. Trends Microbiol. 2016, 24, 902–915. [Google Scholar] [CrossRef] [PubMed]
  24. Maciel-Fiuza, M.F.; Muller, G.C.; Campos, D.M.S.; do Socorro Silva Costa, P.; Veit, T.; Vianna, F.S.L. Role of gut microbiota in infectious and inflammatory diseases. Front. Microbiol. 2023, 14, 1098386. [Google Scholar] [CrossRef] [PubMed]
  25. Koliada, A.; Syzenko, G.; Moseiko, V.; Budovska, L.; Puchkov, K.; Perederiy, V.; Gavalko, Y.; Dorofeyev, A.; Romanenko, M.; Tkach, S. Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. BMC Microbiol 2017, 17, 120. [Google Scholar] [CrossRef] [PubMed]
  26. Mariat, D.; Firmesse, O.; Levenez, F.; Guimarăes, V.D.; Sokol, H.; Doré, J.; Corthier, G.; Furet, J. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 2009, 9, 123. [Google Scholar] [CrossRef]
  27. Cao, S.Y.; Zhao, C.N.; Xu, X.Y.; Tang, G.Y.; Corke, H.; Gan, R.Y.; Li, H. Dietary plants, gut microbiota, and obesity: Effects and mechanisms. Trends Food Sci. Technol. 2019, 92, 194–204. [Google Scholar] [CrossRef]
  28. Barczynska, R.; Kapusniak, J.; Litwin, M.; Slizewska, K.; Szalecki, M. Dextrins from maize starch as substances activating the growth of bacteroidetes and actinobacteria simultaneously inhibiting the growth of firmicutes, responsible for the occurrence of obesity. Plant Foods Hum. Nutr. 2016, 71, 190–196. [Google Scholar] [CrossRef]
  29. Ghosh, S.; Pramanik, S. Structural diversity, functional aspects and future therapeutic applications of human gut microbiome. Arch. Microbiol. 2021, 203, 5281–5308. [Google Scholar] [CrossRef]
  30. Selvakumar, D.; Evans, D.; Coyte, K.Z.; McLaughlin, J.; Brass, A.; Hancock, L.; Cruickshank, S. Understanding the development and function of the gut microbiota in health and inflammation. Frontline Gastroenterol. 2022, 13, e13–e21. [Google Scholar] [CrossRef]
  31. Zheng, D.; Liwinski, T.; Elinav, E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020, 30, 492–506. [Google Scholar] [CrossRef]
  32. Rinninella, E.; Raoul, P.; Cintoni, M.; Franceschi, F.; Miggiano, G.A.D.; Gasbarrini, A.; Mele, M.C. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms 2019, 7, 14. [Google Scholar] [CrossRef]
  33. Kingsland, J. Gut Bacteria Can Help Rebuild the Immune System. Medical News Today 2020. Available online: https://www.medicalnewstoday.com/articles/gut-bacteria-can-help-rebuild-the-immune-system (accessed on 7 November 2024).
  34. Schluter, J.; Peled, J.U.; Taylor, B.P.; Markey, K.A.; Smith, M.; Taur, Y.; Niehus, R.; Staffas, A.; Dai, A.; Fontana, E. The gut microbiota is associated with immune cell dynamics in humans. Nature 2020, 588, 303–307. [Google Scholar] [CrossRef]
  35. Binda, C.; Lopetuso, L.R.; Rizzatti, G.; Gibiino, G.; Cennamo, V.; Gasbarrini, A. Actinobacteria: A relevant minority for the maintenance of gut homeostasis. Dig. Liver Dis. 2018, 50, 421–428. [Google Scholar] [CrossRef] [PubMed]
  36. Pongen, Y.L.; Thirumurugan, D.; Ramasubburayan, R.; Prakash, S. Harnessing actinobacteria potential for cancer prevention and treatment. Microb. Pathog. 2023, 183, 106324. [Google Scholar] [CrossRef] [PubMed]
  37. Li, J.; Si, H.; Du, H.; Guo, H.; Dai, H.; Xu, S.; Wan, J. Comparison of gut microbiota structure and Actinobacteria abundances in healthy young adults and elderly subjects: A pilot study. BMC Microbiol. 2021, 21, 13. [Google Scholar] [CrossRef] [PubMed]
  38. Yoo, J.Y.; Sniffen, S.; McGill Percy, K.C.; Pallaval, V.B.; Chidipi, B. Gut dysbiosis and immune system in atherosclerotic cardiovascular disease (ACVD). Microorganisms 2022, 10, 108. [Google Scholar] [CrossRef]
  39. Afzaal, M.; Saeed, F.; Shah, Y.A.; Hussain, M.; Rabail, R.; Socol, C.T.; Hassoun, A.; Pateiro, M.; Lorenzo, J.M.; Rusu, A.V.; et al. Human gut microbiota in health and disease: Unveiling the relationship. Front. Microbiol. 2022, 13, 999001. [Google Scholar] [CrossRef]
  40. Robertson, R. How Does Your Gut Microbiome Impact Your Overall Health? Healthline Media 2023. Available online: https://www.healthline.com/nutrition/gut-microbiome-and-health (accessed on 11 November 2024).
  41. Rizzatti, G.; Lopetuso, L.R.; Gibiino, G.; Binda, C.; Gasbarrini, A. Proteobacteria: A Common Factor in Human Diseases. Biomed. Res. Int. 2017, 2017, 9351507. [Google Scholar] [CrossRef]
  42. Chakrabarti, A.; Geurts, L.; Hoyles, L.; Iozzo, P.; Kraneveld, A.D.; La Fata, G.; Miani, M.; Patterson, E.; Pot, B.; Shortt, C. The microbiota–gut–brain axis: Pathways to better brain health. Perspectives on what we know, what we need to investigate and how to put knowledge into practice. Cell. Mol. Life Sci. 2022, 79, 80. [Google Scholar] [CrossRef]
  43. Kumar, S.; Kumar, A. Microbial pathogenesis in inflammatory bowel diseases. Microb. Pathog. 2022, 163, 105383. [Google Scholar] [CrossRef]
  44. La Fata, G.; Weber, P.; Mohajeri, M.H. Probiotics and the gut immune system: Indirect regulation. Probiotics Antimicrob. Proteins 2018, 10, 11–21. [Google Scholar] [CrossRef]
  45. Igai, K.; Itakura, M.; Nishijima, S.; Tsurumaru, H.; Suda, W.; Tsutaya, T.; Tomitsuka, E.; Tadokoro, K.; Baba, J.; Odani, S.; et al. Nitrogen fixation and nifH diversity in human gut microbiota. Sci. Rep. 2016, 6, 31942. [Google Scholar] [CrossRef] [PubMed]
  46. Bradley, P.H.; Pollard, K.S. Proteobacteria explain significant functional variability in the human gut microbiome. Microbiome 2017, 5, 36. [Google Scholar] [CrossRef] [PubMed]
  47. Wang, X.; Zhang, P.; Zhang, X. Probiotics regulate gut microbiota: An effective method to improve immunity. Molecules 2021, 26, 6076. [Google Scholar] [CrossRef]
  48. She, J.J.; Liu, W.X.; Ding, X.M.; Guo, G.; Han, J.; Shi, F.Y.; Lau, H.C.H.; Ding, C.G.; Xue, W.J.; Shi, W.; et al. Defining the biogeographical map and potential bacterial translocation of microbiome in human ‘surface organs’. Nat. Commun. 2024, 15, 427. [Google Scholar] [CrossRef] [PubMed]
  49. Guglielmi, G. Gut microbiome discovery provides roadmap for life-saving cancer therapies. Nature 2024. ahead of print. [Google Scholar] [CrossRef]
  50. Wu, H.; Forslund, S.; Wang, Z.; Zhao, G. Human Gut Microbiome Researches Over the Last Decade: Current Challenges and Future Directions. Phenomics 2023, 1–7. [Google Scholar] [CrossRef]
  51. Park, J.; Kato, K.; Murakami, H.; Hosomi, K.; Tanisawa, K.; Nakagata, T.; Ohno, H.; Konishi, K.; Kawashima, H.; Chen, Y.A.; et al. Comprehensive analysis of gut microbiota of a healthy population and covariates affecting microbial variation in two large Japanese cohorts. BMC Microbiol. 2021, 21, 151. [Google Scholar] [CrossRef]
  52. Shi, F.; Liu, G.; Lin, Y.; Guo, C.L.; Han, J.; Chu, E.S.H.; Shi, C.; Li, Y.; Zhang, H.; Hu, C.; et al. Altered gut microbiome composition by appendectomy contributes to colorectal cancer. Oncogene 2023, 42, 530–540. [Google Scholar] [CrossRef]
  53. Motta, J.P.; Wallace, J.L.; Buret, A.G.; Deraison, C.; Vergnolle, N. Gastrointestinal biofilms in health and disease. Nat. Rev. Gastroenterol. Hepatol. 2021, 18, 314–334. [Google Scholar] [CrossRef]
  54. Valdes, A.M.; Walter, J.; Segal, E.; Spector, T.D. Role of the gut microbiota in nutrition and health. BMJ 2018, 361, 36–44. [Google Scholar] [CrossRef]
  55. Smith, H.F.; Parker, W.; Kotzé, S.H.; Laurin, M. Morphological evolution of the mammalian cecum and cecal appendix. C. R. Pale. 2017, 16, 39–57. [Google Scholar] [CrossRef]
  56. Du Toit, A. Bacterial architects build the biofilm structures. Nat. Rev. Microbiol. 2024, 22, 187. [Google Scholar] [CrossRef]
  57. Mak, T.W.; Saunders, M.E. Cells and Tissues of the Immune Response. In The Immune Response; Academic Press: New York, NY, USA, 2006; pp. 35–67. [Google Scholar] [CrossRef]
  58. de Costa, A. The appendix-mucosal immunity and tolerance in the gut: Consequences for the syndromes of appendicitis and its epidemiology. ANZ J. Surg. 2022, 92, 653–660. [Google Scholar] [CrossRef]
  59. Lajqi, T.; Köstlin-Gille, N.; Bauer, R.; Zarogiannis, S.G.; Lajqi, E.; Ajeti, V.; Dietz, S.; Kranig, S.A.; Rühle, J.; Demaj, A.; et al. Training vs. Tolerance: The Yin/Yang of the Innate Immune System. Biomedicines 2023, 11, 766. [Google Scholar] [CrossRef]
  60. Huffaker, M.F.; Sanda, S.; Chandran, S.; Chung, S.A.; St Clair, E.W.; Nepom, G.T.; Smilek, D.E. Approaches to Establishing Tolerance in Immune Mediated Diseases. Front. Immunol. 2021, 12, 744804. [Google Scholar] [CrossRef]
  61. Randal Bollinger, R.; Barbas, A.S.; Bush, E.L.; Lin, S.S.; Parker, W.; Bollinger, R.R.; Barbas, A.S.; Bush, E.L.; Lin, S.S.; Parker, W. Biofilms in the large bowel suggest an apparent function of the human vermiform appendix. J. Theor. Biol. 2007, 249, 826–831. [Google Scholar] [CrossRef] [PubMed]
  62. Wei, H.; Chen, L.; Lian, G.; Yang, J.; Li, F.; Zou, Y.; Lu, F.; Yin, Y. Antitumor mechanisms of bifidobacteria. Oncol. Lett. 2018, 16, 3–8. [Google Scholar] [CrossRef] [PubMed]
  63. Verma, A.; Shukla, G. Probiotics Lactobacillus rhamnosus GG, Lactobacillus acidophilus suppresses DMH-induced procarcinogenic fecal enzymes and preneoplastic aberrant crypt foci in early colon carcinogenesis in Sprague Dawley rats. Nutr. Cancer 2013, 65, 84–91. [Google Scholar] [CrossRef]
  64. Singh, J.; Rivenson, A.; Tomita, M.; Shimamura, S.; Ishibashi, N.; Reddy, B.S. Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis. Carcinogenesis 1997, 18, 833–841. [Google Scholar] [CrossRef]
  65. Lee, D.K.; Jang, S.; Baek, E.H.; Kim, M.J.; Lee, K.S.; Shin, H.S.; Chung, M.J.; Kim, J.E.; Lee, K.O.; Ha, N.J. Lactic acid bacteria affect serum cholesterol levels, harmful fecal enzyme activity, and fecal water content. Lipids Health Dis. 2009, 8, 21. [Google Scholar] [CrossRef]
  66. Arjomand Fard, N.; Armstrong, H.; Perry, T.; Wine, E. Appendix and Ulcerative Colitis: A Key to Explaining the Pathogenesis and Directing Novel Therapies? Inflamm. Bowel Dis. 2023, 29, 151–160. [Google Scholar] [CrossRef]
  67. Mager, L.F.; Burkhard, R.; Pett, N.; Cooke, N.C.A.; Brown, K.; Ramay, H.; Paik, S.; Stagg, J.; Groves, R.A.; Gallo, M.; et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 2020, 369, 1481–1489. [Google Scholar] [CrossRef] [PubMed]
  68. Bennington-Castro, J.; Kacy Church, M. What Is an Appendix, and What Does It Do? Everyday Health 2022. Available online: https://www.everydayhealth.com/appendicitis/guide/appendix/ (accessed on 22 August 2024).
  69. Mattar, A.F.; Drongowski, R.A.; Coran, A.G.; Harmon, C.M. Effect of probiotics on enterocyte bacterial translocation in vitro. Pediatr. Surg. Int. 2001, 17, 265–268. [Google Scholar] [CrossRef] [PubMed]
  70. Mack, D.R.; Ahrne, S.; Hyde, L.; Wei, S.; Hollingsworth, M.A. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 2003, 52, 827–833. [Google Scholar] [CrossRef] [PubMed]
  71. Banasaz, M.; Norin, E.; Holma, R.; Midtvedt, T. Increased enterocyte production in gnotobiotic rats mono-associated with Lactobacillus rhamnosus GG. Appl. Environ. Microbiol. 2002, 68, 3031–3034. [Google Scholar] [CrossRef]
  72. Zhang, X.; Chen, B.-d.; Zhao, L.-d.; Li, H. The Gut Microbiota: Emerging Evidence in Autoimmune Diseases. Trends Mol. Med. 2020, 26, 862–873. [Google Scholar] [CrossRef]
  73. Xu, H.; Liu, M.; Cao, J.; Li, X.; Fan, D.; Xia, Y.; Lu, X.; Li, J.; Ju, D.; Zhao, H.; et al. The Dynamic Interplay between the Gut Microbiota and Autoimmune Diseases. J. Immunol. Res. 2019, 2019, 7546047. [Google Scholar] [CrossRef]
  74. Brody, H. The gut microbiome. Nature 2020, 577, S5. [Google Scholar] [CrossRef]
  75. Wang, L.; Guo, G.; Xu, Y.; Li, L.; Yang, B.; Zhao, D.; Tian, H.; Ye, C.; Lin, Z.; Cui, J.; et al. The effect of fecal microbiota transplantation on antibiotic-associated diarrhea and its impact on gut microbiota. BMC Microbiol. 2024, 24, 160. [Google Scholar] [CrossRef]
  76. Olivares, M.; Neef, A.; Castillejo, G.; De Palma, G.; Varea, V.; Capilla, A.; Palau, F.; Nova, E.; Marcos, A.; Polanco, I.; et al. The HLA-DQ2 genotype selects for early intestinal microbiota composition in infants at high risk of developing coeliac disease. Gut 2015, 64, 406–417. [Google Scholar] [CrossRef]
  77. Collard, M.K.; Tourneur-Marsille, J.; Uzzan, M.; Albuquerque, M.; Roy, M.; Dumay, A.; Freund, J.N.; Hugot, J.P.; Guedj, N.; Treton, X.; et al. The Appendix Orchestrates T-Cell Mediated Immunosurveillance in Colitis-Associated Cancer. Cell Mol. Gastroenterol. Hepatol. 2023, 15, 665–687. [Google Scholar] [CrossRef] [PubMed]
  78. Ramos, G.P.; Papadakis, K.A. Mechanisms of Disease: Inflammatory Bowel Diseases. Mayo Clin. Proc. 2019, 94, 155–165. [Google Scholar] [CrossRef] [PubMed]
  79. Zhang, D.; Tu, E.; Kasagi, S.; Zanvit, P.; Chen, Q.; Chen, W. Manipulating regulatory T cells: A promising strategy to treat autoimmunity. Immunotherapy 2015, 7, 1201–1211. [Google Scholar] [CrossRef]
  80. Takahashi, D.; Hoshina, N.; Kabumoto, Y.; Maeda, Y.; Suzuki, A.; Tanabe, H.; Isobe, J.; Yamada, T.; Muroi, K.; Yanagisawa, Y. Microbiota-derived butyrate limits the autoimmune response by promoting the differentiation of follicular regulatory T cells. eBioMedicine 2020, 58, 102913. [Google Scholar] [CrossRef]
  81. Smith, H.F.; Parker, W.; Kotzé, S.H.; Laurin, M. Multiple independent appearances of the cecal appendix in mammalian evolution and an investigation of related ecological and anatomical factors. C. R. Pale. 2013, 12, 339–354. [Google Scholar] [CrossRef]
  82. Sanders, N.L.; Bollinger, R.R.; Lee, R.; Thomas, S.; Parker, W. Appendectomy and Clostridium difficile colitis: Relationships revealed by clinical observations and immunology. World J. Gastroenterol. WJG 2013, 19, 5607. [Google Scholar] [CrossRef] [PubMed]
  83. Im, G.Y.; Modayil, R.J.; Lin, C.T.; Geier, S.J.; Katz, D.S.; Feuerman, M.; Grendell, J.H. The appendix may protect against Clostridium difficile recurrence. Clin. Gastroenterol. Hepatol. 2011, 9, 1072–1077. [Google Scholar] [CrossRef]
  84. Hrabe, J. Neuroendocrine Tumors of the Appendix, Colon, and Rectum. Surg. Oncol. Clin. N. Am. 2020, 29, 267–279. [Google Scholar] [CrossRef]
  85. Osueni, A.; Chowdhury, Y.S. Appendix Cancer; StatPearls: Tampa. FL, USA, 2023. [Google Scholar]
  86. Imhann, F.; Bonder, M.J.; Vila, A.V.; Fu, J.; Mujagic, Z.; Vork, L.; Tigchelaar, E.F.; Jankipersadsing, S.A.; Cenit, M.C.; Harmsen, H.J.M. Proton pump inhibitors affect the gut microbiome. Gut 2016, 65, 740–748. [Google Scholar] [CrossRef]
  87. Shkoporov, A.N.; Khokhlova, E.V.; Fitzgerald, C.B.; Stockdale, S.R.; Draper, L.A.; Ross, R.P.; Hill, C. ΦCrAss001 represents the most abundant bacteriophage family in the human gut and infects Bacteroides intestinalis. Nat. Commun. 2018, 9, 4781. [Google Scholar] [CrossRef]
  88. Vyas, U.; Ranganathan, N. Probiotics, prebiotics, and synbiotics: Gut and beyond. Gastroenterol. Res. Pract. 2012, 2012, 872716. [Google Scholar] [CrossRef]
  89. Tana, C.; Umesaki, Y.; Imaoka, A.; Handa, T.; Kanazawa, M.; Fukudo, S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol. Motil. 2010, 22, 512-e115. [Google Scholar] [CrossRef] [PubMed]
  90. Osadchiy, V.; Martin, C.R.; Mayer, E.A. The Gut–Brain Axis and the Microbiome: Mechanisms and Clinical Implications. Clin. Gastroenterol. Hepatol. 2019, 17, 322–332. [Google Scholar] [CrossRef]
  91. Poojara, L.; Acharya, D.K.; Patel, J.; Rawal, R.M. Gut–Brain Axis: Role of the Gut Microbiome on Human Health. In Microbiome-Gut-Brain Axis; Springer: Berlin/Heidelberg, Germany, 2022; pp. 187–211. [Google Scholar] [CrossRef]
  92. Rankin, L.C.; Girard-Madoux, M.J.H.; Seillet, C.; Mielke, L.A.; Kerdiles, Y.; Fenis, A.; Wieduwild, E.; Putoczki, T.; Mondot, S.; Lantz, O.; et al. Complementarity and redundancy of IL-22-producing innate lymphoid cells. Nat. Immunol. 2016, 17, 179–186. [Google Scholar] [CrossRef] [PubMed]
  93. Bonanni, P.; Grazzini, M.; Niccolai, G.; Paolini, D.; Varone, O.; Bartoloni, A.; Bartalesi, F.; Santini, M.G.; Baretti, S.; Bonito, C.; et al. Recommended vaccinations for asplenic and hyposplenic adult patients. Hum. Vaccin. Immunother. 2017, 13, 359–368. [Google Scholar] [CrossRef]
  94. Sánchez-Alcoholado, L.; Fernández-García, J.C.; Gutiérrez-Repiso, C.; Bernal-López, M.R.; Ocaña-Wilhelmi, L.; García-Fuentes, E.; Moreno-Indias, I.; Tinahones, F.J. Incidental Prophylactic Appendectomy Is Associated with a Profound Microbial Dysbiosis in the Long-Term. Microorganisms 2020, 8, 609. [Google Scholar] [CrossRef] [PubMed]
  95. Wang, Z.; Bao, L.; Wu, L.; Zeng, Q.; Feng, Q.; Zhou, J.; Luo, Z.; Wang, Y. Causal effects of gut microbiota on appendicitis: A two-sample Mendelian randomization study. Front. Cell Infect. Microbiol. 2023, 13, 1320992. [Google Scholar] [CrossRef]
  96. Bensch, H.M.; Tolf, C.; Waldenström, J.; Lundin, D.; Zöttl, M. Bacteroidetes to Firmicutes: Captivity changes the gut microbiota composition and diversity in a social subterranean rodent. Anim. Microbiome. 2023, 5, 9. [Google Scholar] [CrossRef]
  97. Vaiserman, A.; Romanenko, M.; Piven, L.; Moseiko, V.; Lushchak, O.; Kryzhanovska, N.; Guryanov, V.; Koliada, A. Differences in the gut Firmicutes to Bacteroidetes ratio across age groups in healthy Ukrainian population. BMC Microbiol. 2020, 20, 221. [Google Scholar] [CrossRef]
  98. Ergul, E.; Gozetlik, E.O. Does appendectomy increase the risk of colorectal adenocarcinoma? Cent. Eur. J. Med. 2009, 4, 315–319. [Google Scholar] [CrossRef]
  99. Wu, S.C.; Chen, W.T.L.; Muo, C.H.; Ke, T.W.; Fang, C.W.; Sung, F.C. Association between appendectomy and subsequent colorectal cancer development: An Asian population study. PLoS ONE 2015, 10, e0118411. [Google Scholar] [CrossRef] [PubMed]
  100. Shi, F.; Liu, G.; Lin, Y.; Guo, C.L.; Han, J.; She, J. IDDF2021-ABS-0054 Appendectomy increases the risk of colorectal cancer through causing gut microbiota dysbiosis in a large population-based study. Gut 2021, 70, A17–A19. [Google Scholar] [CrossRef]
  101. Sánchez-Alcoholado, L.; Ramos-Molina, B.; Otero, A.; Laborda-Illanes, A.; Ordóñez, R.; Medina, J.A.; Gómez-Millán, J.; Queipo-Ortuño, M.I. The role of the gut microbiome in colorectal cancer development and therapy response. Cancers 2020, 12, 1406. [Google Scholar] [CrossRef] [PubMed]
  102. Rasmussen, T.; Fonnes, S.; Rosenberg, J. Long-Term Complications of Appendectomy: A Systematic Review. Scand. J. Surg. 2018, 107, 189–196. [Google Scholar] [CrossRef]
  103. Liu, Z.; Ma, X.; Zhu, C.; Fang, J.Y. Risk of colorectal cancer after appendectomy: A systematic review and meta-analysis. J. Gastroenterol. Hepatol. 2023, 38, 350–358. [Google Scholar] [CrossRef] [PubMed]
  104. Fantodji, C.; Jantchou, P.; Parent, M.E.; Rousseau, M.C. Appendectomy and risk for inflammatory bowel disease: Effect of age and time post appendectomy—A cohort study. BMJ Open Gastroenterol. 2022, 9, e000925. [Google Scholar] [CrossRef]
  105. Rotem-Kohavi, N.; Keane, J.; Clarke, G.; Dinan, T.G.; Cryan, J.F.; McCarthy, F.P.; Oberlander, T.F.; O’Mahony, S.M. The microbiome-gut-brain axis: A new window to view the impact of prenatal stress on early neurodevelopment. In Prenatal Stress and Child Development; Springer: Berlin/Heidelberg, Germany, 2021; pp. 165–191. [Google Scholar] [CrossRef]
  106. Larson, M.E.; Sherman, M.A.; Greimel, S.; Kuskowski, M.; Schneider, J.A.; Bennett, D.A.; Lesné, S.E. Soluble α-Synuclein Is a Novel Modulator of Alzheimer’s Disease Pathophysiology. J. Neurosci. 2012, 32, 10253–10266. [Google Scholar] [CrossRef]
  107. Ábrahám, S.; Németh, T.; Benko, R.; Matuz, M.; Ottlakán, A.; Váczi, D.; Paszt, A.; Simonka, Z.; Lázár, G. Evaluating the distribution of the locations of colorectal cancer after appendectomy and cholecystectomy. World J. Surg. Oncol. 2020, 18, 94. [Google Scholar] [CrossRef]
  108. Wu, S.C.; Chen, W.T.L.; Muo, C.H.; Sung, F.C. Appendicitis as an Early Manifestation of Subsequent Malignancy: An Asian Population Study. PLoS ONE 2015, 10, e0122725. [Google Scholar] [CrossRef]
  109. Ler, A.A.L.; Carty, M.P. DNA Damage Tolerance Pathways in Human Cells: A Potential Therapeutic Target. Front. Oncol. 2022, 11, 822500. [Google Scholar] [CrossRef]
  110. Rivas-Domínguez, A.; Pastor, N.; Martínez-López, L.; Colón-Pérez, J.; Bermúdez, B.; Orta, M.L. The role of DNA damage response in dysbiosis-induced colorectal cancer. Cells 2021, 10, 1934. [Google Scholar] [CrossRef] [PubMed]
  111. Anderson, S.M.; Sears, C.L. The Role of the Gut Microbiome in Cancer: A Review, With Special Focus on Colorectal Neoplasia and Clostridioides difficile. Clin. Infect. Dis. 2023, 77, S471–S478. [Google Scholar] [CrossRef]
  112. Bossuet-Greif, N.; Vignard, J.; Taieb, F.; Mirey, G.; Dubois, D.; Petit, C.; Oswald, E.; Nougayrède, J.-P. The colibactin genotoxin generates DNA interstrand cross-links in infected cells. mBio 2018, 9, e02393-17. [Google Scholar] [CrossRef]
  113. Kamath, H.S.; Shukla, R.; Shah, U.; Patel, S.; Das, S.; Chordia, A.; Satish, P.; Ghosh, D. Role of Gut Microbiota in Predisposition to Colon Cancer: A Narrative Review. Indian J. Microbiol. 2024, 64, 1–13. [Google Scholar] [CrossRef]
  114. Kunst, C.; Schmid, S.; Michalski, M.; Tümen, D.; Buttenschön, J.; Müller, M.; Gülow, K. The influence of gut microbiota on oxidative stress and the immune system. Biomedicines 2023, 11, 1388. [Google Scholar] [CrossRef] [PubMed]
  115. Dam, B.; Misra, A.; Banerjee, S. Role of gut microbiota in combating oxidative stress. In Oxidative Stress in Microbial Diseases; Springer: Berlin/Heidelberg, Germany, 2019; pp. 43–82. [Google Scholar]
  116. Sun, Y.; Wang, X.; Li, L.; Zhong, C.; Zhang, Y.; Yang, X.; Li, M.; Yang, C. The role of gut microbiota in intestinal disease: From an oxidative stress perspective. Front. Microbiol. 2024, 15, 1328324. [Google Scholar] [CrossRef] [PubMed]
  117. Kawamura, H.; Ugai, T.; Takashima, Y.; Okadome, K.; Shimizu, T.; Mima, K.; Akimoto, N.; Haruki, K.; Arima, K.; Zhao, M.; et al. Appendectomy and Long-term Colorectal Cancer Incidence, Overall and by Tumor Fusobacterium nucleatum Status. Ann. Surg. 2024. ahead of print. [Google Scholar] [CrossRef]
  118. van den Boom, A.L.; Lavrijssen, B.D.A.; Fest, J.; Ikram, M.A.; Stricker, B.H.; van Eijck, C.H.J.; Ruiter, R. Appendectomy and the subsequent risk of cancer: A prospective population-based cohort study with long follow-up. Cancer Epidemiol. 2022, 77, 102120. [Google Scholar] [CrossRef]
  119. Mohammadi, M.; Song, H.; Cao, Y.; Glimelius, I.; Ekbom, A.; Ye, W.; Smedby, K.E. Risk of lymphoid neoplasms in a Swedish population-based cohort of 337,437 patients undergoing appendectomy. Scand. J. Gastroenterol. 2016, 51, 583–589. [Google Scholar] [CrossRef]
  120. Lee, J.; Choe, S.; Park, J.W.; Jeong, S.Y.; Shin, A. The Risk of Colorectal Cancer After Cholecystectomy or Appendectomy: A Population-based Cohort Study in Korea. J. Prev. Med. Public Health 2018, 51, 281–288. [Google Scholar] [CrossRef]
  121. Mark-Christensen, A.; Kristiansen, E.B.; Myrelid, P.; Laurberg, S.; Erichsen, R. Appendectomy and Risk of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: A Nationwide Population-based Cohort Study. Inflamm. Bowel Dis. 2024, 30, 877–883. [Google Scholar] [CrossRef]
  122. Yap, D.R.Y.; Lui, R.N.; Samol, J.; Ngeow, J.; Sung, J.J.Y.Y.; Wong, S.H. Beyond a vestigial organ: Effects of the appendix on gut microbiome and colorectal cancer. J. Gastroenterol. Hepatol. 2024, 39, 826–835. [Google Scholar] [CrossRef] [PubMed]
  123. Wei, W.; Wang, J.; Yu, D.; Liu, W.; Zong, L. Appendectomy and appendicitis do not increase colorectal cancer risk: Evidence from Mendelian randomization. Front. Oncol. 2024, 14, 1414946. [Google Scholar] [CrossRef] [PubMed]
  124. Zhang, Y.; Khil, J.; Feng, X.; Ugai, T.; Ogino, S.; Giovannucci, E. Risk of colorectal cancer and adenoma after an appendectomy: Results from three large prospective cohort studies and meta-analysis. Cancer Causes Control. 2024, 35, 1457–1466. [Google Scholar] [CrossRef]
  125. Liu, G.; Hu, C.; Wei, J.; Li, Q.; Zhang, J.; Zhang, Z.; Qu, P.; Cao, Z.; Wang, R.; Ji, G.; et al. The association of appendectomy with prognosis and tumor-associated macrophages in patients with colorectal cancer. iScience 2024, 27, 110578. [Google Scholar] [CrossRef]
  126. Vietsch, E.E.; Latifi, D.; Verheij, M.; van der Oost, E.W.A.; de Wilde, R.F.; Haen, R.; Boom, A.L.v.D.; Koerkamp, B.G.; Doornebosch, P.G.; van Verschuer, V.M.; et al. B cell immune profiles in dysbiotic vermiform appendixes of pancreatic cancer patients. Front. Immunol. 2023, 14, 1230306. [Google Scholar] [CrossRef]
  127. Sugihara, K.; Kamada, N. Metabolic network of the gut microbiota in inflammatory bowel disease. Inflamm. Regen. 2024, 44, 11. [Google Scholar] [CrossRef] [PubMed]
  128. Chung, W.S.; Chung, S.; Hsu, C.Y.; Lin, C.L. Risk of Inflammatory Bowel Disease Following Appendectomy in Adulthood. Front. Med. 2021, 8, 661752. [Google Scholar] [CrossRef]
  129. Gardenbroek, T.J.; Eshuis, E.J.; Ponsioen, C.I.J.; Ubbink, D.T.; D’Haens, G.R.A.M.; Bemelman, W.A. The effect of appendectomy on the course of ulcerative colitis: A systematic review. Color. Dis. 2012, 14, 545–553. [Google Scholar] [CrossRef]
  130. Andersson, R.E.; Olaison, G.; Tysk, C.; Ekbom, A. Appendectomy and Protection against Ulcerative Colitis. N. Engl. J. Med. 2001, 344, 808–814. [Google Scholar] [CrossRef]
  131. Silen, W. Discussion on appendectomy is followed by increased risk of Crohn’s disease. Gastroenterology 2003, 125, 997. [Google Scholar] [CrossRef] [PubMed]
  132. Loureiro, A.C.C.F.; Barbosa, L.E.R. Appendectomy and Crohn’s Disease. J. Coloproctology 2019, 39, 373–380. [Google Scholar] [CrossRef]
  133. Zhang, L.; Hu, C.; Zhang, Z.; Liu, R.; Liu, G.; Xue, D.; Wang, Z.; Wu, C.; Wu, X.; She, J.; et al. Association between prior appendectomy and the risk and course of Crohn’s disease: A systematic review and meta-analysis. Clin. Res. Hepatol. Gastroenterol. 2023, 47, 102090. [Google Scholar] [CrossRef] [PubMed]
  134. Gilat, T.; Hacohen, D.; Lilos, P.; Langman, M.J.S. Childhood Factors in Ulcerative Colitis and Crohn’s Disease: An International Cooperative Study. Scand. J. Gastroenterol. 1987, 22, 1009–1024. [Google Scholar] [CrossRef]
  135. Stellingwerf, M.E.; Bemelman, W.A.; Löwenberg, M.; Ponsioen, C.Y.; D’Haens, G.R.; van Dieren, S.; Buskens, C.J. A nationwide database study on colectomy and colorectal cancer in ulcerative colitis: What is the role of appendectomy? Color. Dis. 2021, 23, 64–73. [Google Scholar] [CrossRef]
  136. Blohs, M.; Mahnert, A.; Brunnader, K.; Flucher, C.; Castellani, C.; Till, H.; Singer, G.; Moissl-Eichinger, C. Acute appendicitis manifests as two microbiome state types with oral pathogens influencing severity. Gut Microbes 2023, 15, 2145845. [Google Scholar] [CrossRef]
  137. Ma, Y.; Zhang, Y.; Xiang, J.; Xiang, S.; Zhao, Y.; Xiao, M.; Du, F.; Ji, H.; Kaboli, P.J.; Wu, X.; et al. Metagenome Analysis of Intestinal Bacteria in Healthy People, Patients with Inflammatory Bowel Disease and Colorectal Cancer. Front. Cell Infect. Microbiol. 2021, 11, 599734. [Google Scholar] [CrossRef]
  138. Sanat, Z.M.; Vahedi, H.; Malekzadeh, R.; Fanni, Z. Epidemiologic profile of inflammatory bowel disease in Eastern Mediterranean Region (EMRO) countries: A systematic review and meta-analysis. BMC Public Health 2024, 24, 1395. [Google Scholar] [CrossRef]
  139. Amin, R.; Mansabdar, A.; Gu, H.; Gangineni, B.; Mehta, N.; Patel, H.; Patel, N.; Laller, S.; Vinayak, S.; Abdulqader, M.A.; et al. Mucosa-Associated Lymphoid Tissue Surgeries as a Possible Risk for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Gastroenterol. Res. 2024, 17, 90–99. [Google Scholar] [CrossRef]
  140. Mark-Christensen, A.; Kristiansen, E.B.; Laurberg, S.; Erichsen, R. Prior Appendectomy Is Associated with a Milder Clinical Course in Crohn’s Disease: A Nationwide Population-based Cohort Study. Inflamm. Bowel. Dis. 2025, 31, 123–130. [Google Scholar] [CrossRef]
  141. Dong, S.; Xiang, X.; Zhang, Y.; Liu, R.; Ye, L.; Cao, Q. Differences of clinical phenotype between familial and sporadic Crohn’s disease in East China. Int. J. Colorectal. Dis. 2024, 39, 107. [Google Scholar] [CrossRef] [PubMed]
  142. Stellingwerf, M.E.; De Koning, M.A.; Pinkney, T.; Bemelman, W.A.; D’haens, G.R.; Buskens, C.J. The Risk of Colectomy and Colorectal Cancer After Appendectomy in Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. J. Crohns Colitis 2019, 13, 309–318. [Google Scholar] [CrossRef]
  143. Franko, J. Removing the Appendix: Prologue to Severe Clostridioides difficile Infection and Recurrence? Dig. Dis. Sci. 2023, 68, 3488–3489. [Google Scholar] [CrossRef]
  144. Kyne, L.; Farrell, R.J.; Kelly, C.P. Clostridium difficile. Gastroenterol. Clin. N. Am. 2001, 30, 753–777. [Google Scholar] [CrossRef]
  145. Merchant, R.; Mower, W.R.; Ourian, A.; Abrahamian, F.M.; Moran, G.J.; Krishnadasan, A.; Talan, D.A. Association Between Appendectomy and Clostridium difficile Infection. J. Clin. Med. Res. 2012, 4, 17–19. [Google Scholar] [CrossRef] [PubMed][Green Version]
  146. Poutanen, S.M.; Simor, A.E. Clostridium difficile-associated diarrhea in adults. CMAJ 2004, 171, 51–58. [Google Scholar] [CrossRef]
  147. Shaikh, D.H.; Patel, H.; Munshi, R.; Sun, H.; Mehershahi, S.; Baiomi, A.; Alemam, A.; Pirzada, U.; Nawaz, I.; Naher, K.; et al. Patients with Clostridium difficile infection and prior appendectomy may be prone to worse outcomes. World J. Gastrointest. Surg. 2021, 13, 1436–1447. [Google Scholar] [CrossRef] [PubMed]
  148. Hu, A.; Tian, Y.; Huang, L.; Chaudhury, A.; Mathur, R.; Sullivan, G.A.; Reiter, A.; Raval, M.V. Association Between Common Empiric Antibiotic Regimens and Clostridioides Difficile Infection in Pediatric Appendicitis. J. Pediatr. Surg. 2024, 59, 515–521. [Google Scholar] [CrossRef]
  149. Naga, Y.S.E.; Dhindsa, B.S.; Bapaye, J.; Tun, K.M.; Dhaliwal, A.; Ramai, D.; Saghir, S.M.; Chandan, S.; Adler, D.G. A Systematic Review and Meta-Analysis: A Prior Appendectomy Does Not Increase the Risk of Severe Clostridioides difficile Infection or Recurrence. Dig. Dis. Sci. 2023, 68, 3714–3720. [Google Scholar] [CrossRef]
  150. Kumar, M.; Peters, M.; Karabon, P.; Brahmamdam, P. Clostridioides difficile infection after appendectomy: An analysis of short-term outcomes from the NSQIP database. Surgery 2022, 172, 791–797. [Google Scholar] [CrossRef]
  151. Sadik, K.W.; Hranjec, T.; Bonatti, H.J.R.; Sawyer, R.G. Incidence of Early and Late-Onset Clostridioides difficile Infection following Appendectomy Compared to Other Common Abdominal Surgical Procedures. Surg. Res. Pract. 2022, 2022, 8720144. [Google Scholar] [CrossRef]
  152. Mendes, A.; Gonçalves, A.; Vila-Chã, N.; Moreira, I.; Fernandes, J.; Damásio, J.; Teixeira-Pinto, A.; Taipa, R.; Lima, A.B.; Cavaco, S. Appendectomy may delay Parkinson’s disease Onset. Mov. Disord. 2015, 30, 1404–1407. [Google Scholar] [CrossRef] [PubMed]
  153. Killinger, B.A.; Madaj, Z.; Sikora, J.W.; Rey, N.; Haas, A.J.; Vepa, Y.; Lindqvist, D.; Chen, H.; Thomas, P.M.; Brundin, P.; et al. The vermiform appendix impacts the risk of developing Parkinson’s disease. Sci. Transl. Med. 2018, 10, 465. [Google Scholar] [CrossRef] [PubMed]
  154. Palacios, N.; Hughes, K.C.; Cereda, E.; Schwarzschild, M.A.; Ascherio, A. Appendectomy and risk of Parkinson’s disease in two large prospective cohorts of men and women. Mov. Disord. 2018, 33, 1492–1496. [Google Scholar] [CrossRef] [PubMed]
  155. Nakahara, K.; Nakane, S.; Ishii, K.; Ikeda, T.; Ando, Y. Gut microbiota of Parkinson’s disease in an appendectomy cohort: A preliminary study. Sci. Rep. 2023, 13, 2210. [Google Scholar] [CrossRef]
  156. Sheriff, M.Z.; Mansoor, E.; Cooper, G.S. 739—Parkinson’s Disease is More Prevalent in Patients with Appendectomies: A National Population-Based Study. Gastroenterology 2019, 156, S-1409. [Google Scholar] [CrossRef]
  157. Svensson, E.; Horváth-Puhó, E.; Stokholm, M.G.; Sørensen, H.T.; Henderson, V.W.; Borghammer, P. Appendectomy and risk of Parkinson’s disease: A nationwide cohort study with more than 10 years of follow-up. Mov. Disord. 2016, 31, 1918–1922. [Google Scholar] [CrossRef]
  158. Yilmaz, R.; Bayram, E.; Ulukan, Ç.; Altnok, M.K.; Akbostanc, M.C. Appendectomy History is not Related to Parkinson’s Disease. J. Parkinsons Dis. 2017, 7, 347–352. [Google Scholar] [CrossRef]
  159. Marras, C.; Lang, A.E.; Austin, P.C.; Lau, C.; Urbach, D.R. Appendectomy in mid and later life and risk of Parkinson’s disease: A population-based study. Mov. Disord. 2016, 31, 1243–1247. [Google Scholar] [CrossRef]
  160. Nishiwaki, H.; Ueyama, J.; Ito, M.; Hamaguchi, T.; Takimoto, K.; Maeda, T.; Kashihara, K.; Tsuboi, Y.; Mori, H.; Kurokawa, K.; et al. Meta-analysis of shotgun sequencing of gut microbiota in Parkinson’s disease. N. Park. Dis. 2024, 10, 106. [Google Scholar] [CrossRef]
  161. Ishizuka, M.; Shibuya, N.; Takagi, K.; Hachiya, H.; Tago, K.; Suda, K.; Aoki, T.; Kubota, K. Appendectomy Does Not Increase the Risk of Future Emergence of Parkinson’s Disease: A Meta-analysis. Am. Surg. 2021, 87, 1802–1808. [Google Scholar] [CrossRef]
  162. Lu, H.-T.; Shen, Q.-Y.; Xie, D.; Zhao, Q.-Z.; Xu, Y.-M. Lack of association between appendectomy and Parkinson’s disease: A systematic review and meta-analysis. Aging Clin. Exp. Res. 2020, 32, 2201–2209. [Google Scholar] [CrossRef] [PubMed]
  163. Gonçalves, A.R.; Mendes, A.; Vila-Chã, N.; Damásio, J.; Fernandes, J.; Cavaco, S.M. Past appendectomy may be related to early cognitive dysfunction in Parkinson’s disease. Neurol. Sci. 2021, 42, 123–130. [Google Scholar] [CrossRef] [PubMed]
  164. Liang, C.-S.; Bai, Y.-M.; Hsu, J.-W.; Huang, K.-L.; Chu, C.-S.; Yeh, T.-C.; Tsai, S.-J.; Chen, T.-J.; Chen, M.-H. The Risk of Alzheimer’s Disease After Acute Appendicitis With or Without Appendectomy. J. Am. Med. Dir. Assoc. 2022, 23, 601–607.e2. [Google Scholar] [CrossRef] [PubMed]
  165. Ooi, H.S.; Viswanathan, S.; Botross, N.P.; Eow, G.B.; Chin, Y.T.; Kanesalingam, R.; Isman, M.A.R.; Cheang, J.M.; Nordin, R.B.; Sood, S. Association between Appendectomy and Demyelinating Disorders in Subjects 40 Years and Older. Neurol. India 2020, 68, 850–855. [Google Scholar] [CrossRef]
  166. Ekström, L.D.; Ekström, H.; Dal, H.; Kosidou, K.; Gustafsson, U.O. Childhood appendectomy and adult mental disorders: A population-based cohort study. Depress. Anxiety 2020, 37, 1108–1117. [Google Scholar] [CrossRef]
  167. Snyder, C.W.; Bludevich, B.M.; Gonzalez, R.; Danielson, P.D.; Chandler, N.M. Risk factors for complications after abdominal surgery in children with sickle cell disease. J. Pediatr. Surg. 2021, 56, 711–716. [Google Scholar] [CrossRef]
  168. Cui, C.; Longinetti, E.; Larsson, H.; Andersson, J.; Pawitan, Y.; Piehl, F.; Fang, F. Associations between autoimmune diseases and amyotrophic lateral sclerosis: A register-based study. Amyotroph. Lateral Scler. Front. Degener. 2021, 22, 211–219. [Google Scholar] [CrossRef]
  169. Moris, D.; Pappas, T. Elective Appendectomy Following Antibiotics for Appendicitis. JAMA Surg. 2024, 159, 599–600. [Google Scholar] [CrossRef]
  170. Zarei, S.; Carr, K.; Reiley, L.; Diaz, K.; Guerra, O.; Altamirano, P.F.; Pagani, W.; Lodin, D.; Orozco, G.; Chinea, A. A comprehensive review of amyotrophic lateral sclerosis. Surg. Neurol. Int. 2015, 6, 171. [Google Scholar] [CrossRef]
  171. Bradford, D.; Rodgers, K.E. Advancements and challenges in amyotrophic lateral sclerosis. Front. Neurosci. 2024, 18, 1401706. [Google Scholar] [CrossRef] [PubMed]
  172. Mancuso, C.; Santangelo, R. Alzheimer’s disease and gut microbiota modifications: The long way between preclinical studies and clinical evidence. Pharmacol. Res. 2017, 129, 329–336. [Google Scholar] [CrossRef]
  173. Kim, M.S.; Kim, Y.; Choi, H.; Kim, W.; Park, S.; Lee, D.; Kim, D.K.; Kim, H.J.; Choi, H.; Hyun, D.-W.; et al. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer’s disease animal model. Gut 2020, 69, 283–294. [Google Scholar] [CrossRef]
  174. Tzeng, Y.-M.; Kao, L.-T.; Kao, S.; Lin, H.-C.; Tsai, M.-C.; Lee, C.-Z. An Appendectomy Increases the Risk of Rheumatoid Arthritis: A Five-Year Follow-Up Study. PLoS ONE 2015, 10, e0126816. [Google Scholar] [CrossRef]
  175. Chen, Y.-W.; Hsu, P.-K.; Lin, S.-P.; Chen, H.-H. Appendicitis is associated with an increased risk of systemic lupus erythematosus: A nationwide, population-based, case–control study. Clin. Rheumatol. 2023, 42, 1783–1791. [Google Scholar] [CrossRef]
  176. Hubbard, G.; Chlysta, W. Tuberculous appendicitis: A review of reported cases over the past 10 years. J. Clin. Tuberc. Other Mycobact. Dis. 2021, 23, 100228. [Google Scholar] [CrossRef] [PubMed]
  177. Wang, S.; Zhang, T.; Sun, Y.; Yao, Y.; Yang, D.; Cao, X. Exploring the causality of appendectomy and ischaemic heart disease: A Mendelian randomization study and meta-analysis. Front. Cardiovasc. Med. 2024, 11, 1443906. [Google Scholar] [CrossRef]
  178. Chen, C.H.; Tsai, M.C.; Lin, H.C.; Lee, H.C.; Lee, C.Z.; Chung, S.D. Appendectomy increased the risk of ischemic heart disease. J. Surg. Res. 2015, 199, 435–440. [Google Scholar] [CrossRef] [PubMed]
  179. Perone, J.A.; Riall, T.S. Commentary: Appendectomy and increased the risk of ischemic heart disease. J. Surg. Res. 2016, 200, 36–38. [Google Scholar] [CrossRef]
  180. Janszky, I.; Mukamal, K.J.; Dalman, C.; Hammar, N.; Ahnve, S. Childhood appendectomy, tonsillectomy, and risk for premature acute myocardial infarction—A nationwide population-based cohort study. Eur. Heart J. 2011, 32, 2290–2296. [Google Scholar] [CrossRef]
  181. Kim, S.Y.; Oh, D.J.; Park, B.; Park, I.S.; Choi, H.G.; Ekizoglu, O. Increased risk of appendectomy in patients with asthma: A nested case-control study using a national sample cohort. Medicine 2019, 98, e17203. [Google Scholar] [CrossRef] [PubMed]
  182. Lee, Y.M.; Kor, C.T.; Zhou, D.; Lai, H.C.; Chang, C.C.; Ma, W.L. Impact of age at appendectomy on development of type 2 diabetes: A population-based cohort study. PLoS ONE 2018, 13, e0205502. [Google Scholar] [CrossRef]
  183. Chiang, H.Y.; Lin, K.T.R.; Hsiao, Y.L.; Huang, H.C.; Chang, S.N.; Hung, C.H.; Chang, Y.; Wang, Y.-C.; Kuo, C.-C. Association Between Preoperative Blood Glucose Level and Hospital Length of Stay for Patients Undergoing Appendectomy or Laparoscopic Cholecystectomy. Diabetes Care 2021, 44, 107–115. [Google Scholar] [CrossRef] [PubMed]
  184. Yin, P.; Teng, S.; Li, H.; Wang, J.; Liu, Z. Association between body composition and incisional surgical site infection after laparoscopic appendectomy for complicated appendicitis. BMC Surg. 2024, 24, 297. [Google Scholar] [CrossRef]
  185. Wei, L.; MacDonald, T.; Shimi, S. Association between appendicectomy in females and subsequent pregnancy rate: A cohort study. Fertil. Steril. 2012, 98, 401–405. [Google Scholar] [CrossRef]
  186. Wei, L.; MacDonald, T.M.; Shimi, S.M. Appendicectomy is associated with increased pregnancy rate: A cohort study. Ann. Surg. 2012, 256, 1039–1044. [Google Scholar] [CrossRef]
  187. Wei, L.; MacDonald, T.; Shimi, S. Association between prior appendectomy and/or tonsillectomy in women and subsequent pregnancy rate: A cohort study. Fertil. Steril. 2016, 106, 1150–1156. [Google Scholar] [CrossRef]
  188. Kummer, J.; Koenigbauer, J.; Peters, F.S.J.; Rickert, C.; Hellmeyer, L. Is Appendectomy During Late Stages of Pregnancy Associated with an Increased Cesarean Delivery Rate?—A Retrospective Analysis of One Center During 10 Years. Geburtshilfe Frauenheilkd 2024, 84, 378–386. [Google Scholar] [CrossRef] [PubMed]
  189. Andersson, R.E. Short and long-term mortality after appendectomy in Sweden 1987 to 2006. Influence of appendectomy diagnosis, sex, age, co-morbidity, surgical method, hospital volume, and time period. A national population-based cohort study. World J. Surg. 2013, 37, 974–981. [Google Scholar] [CrossRef]
  190. Angenete, E.; Jacobsson, A.; Gellerstedt, M.; Haglind, E. Effect of laparoscopy on the risk of small-bowel obstruction: A population-based register study. Arch. Surg. 2012, 147, 359–365. [Google Scholar] [CrossRef]
  191. Krieg, S.; Kolbe, E.W.; Loosen, S.H.; Roderburg, C.; Krieg, A.; Kostev, K. Is there a link between appendicitis and the risk of diverticular disease?: A large German cohort study. Int. J. Colorectal. Dis. 2024, 39, 50. [Google Scholar] [CrossRef]
  192. Niu, C.; Xu, W.; Xiong, S. Appendectomy Mitigates Coxsackievirus B3-Induced Viral Myocarditis. Viruses 2023, 15, 1974. [Google Scholar] [CrossRef]
  193. Young, E.; Stewart, S.; McCulloch, G.A.J.; Maddern, G.J. Appendicectomy mortality: An Australian national audit. ANZ J. Surg. 2019, 89, 1441–1445. [Google Scholar] [CrossRef] [PubMed]
  194. Buitrago, G.; Junca, E.; Eslava-Schmalbach, J.; Caycedo, R.; Pinillos, P.; Leal, L.C. Clinical Outcomes and Healthcare Costs Associated with Laparoscopic Appendectomy in a Middle-Income Country with Universal Health Coverage. World J. Surg. 2019, 43, 67–74. [Google Scholar] [CrossRef] [PubMed]
  195. Fernández-Moreno, M.C.; Pérez Santiago, L.; Martí Fernández, R.; León Espinoza, C.; Ortega Serrano, J. Is laparoscopic approach still a risk factor for postappendectomy intra-abdominal abscess? J. Trauma Acute Care. Surg. 2021, 90, 163–169. [Google Scholar] [CrossRef]
  196. Sugai, S.; Sasabuchi, Y.; Yasunaga, H.; Aso, S.; Matsui, H.; Fushimi, K.; Yoshihara, K.; Nishijima, K. Comparison of open and laparoscopic appendectomy according to the trimester of pregnancy: A nationwide observational study. World J. Surg. 2024, 49, 74–81. [Google Scholar] [CrossRef]
  197. Lindqvist, P.G.; Pettersson, H.; Dahlberg, M.; Sandblom, G.; Boström, L. Appendectomy during pregnancy: Rates, safety, and outcomes over a five-year period. A hospital-based follow-up study. J. Matern.-Fetal Neonatal Med. 2023, 36, 2160629. [Google Scholar] [CrossRef] [PubMed]
  198. Lee, J.H.; Choi, J.Y.; Kim, Y.J. Safety of laparoscopic surgery during pregnancy: A Korean nationwide population-based study. Surg. Endosc. 2022, 36, 7529–7540. [Google Scholar] [CrossRef]
  199. Choi, H.G.; Oh, D.J.; Kim, M.; Kim, S.; Min, C.; Kong, I.G. Appendectomy and rheumatoid arthritis: A longitudinal follow-up study using a national sample cohort. Medicine 2019, 98, e17153. [Google Scholar] [CrossRef]
  200. Chung, W.S.; Lin, C.L.; Hsu, C.Y. Women who had appendectomy have increased risk of systemic lupus erythematosus: A nationwide cohort study. Clin. Rheumatol. 2018, 37, 3009–3016. [Google Scholar] [CrossRef]
  201. Bunn, C.; Kulshrestha, S.; Boyda, J.; Balasubramanian, N.; Birch, S.; Karabayir, I.; Baker, M.; Luchette, F.; Modave, F.; Akbilgic, O. Application of machine learning to the prediction of postoperative sepsis after appendectomy. Surgery 2021, 169, 671–677. [Google Scholar] [CrossRef] [PubMed]
  202. Gyriki, D.; Nikolaidis, C.; Stavropoulou, E.; Bezirtzoglou, I.; Tsigalou, C.; Vradelis, S.; Bezirtzoglou, E. Exploring the Gut Microbiome’s Role in Inflammatory Bowel Disease: Insights and Interventions. J. Pers. Med. 2024, 14, 507. [Google Scholar] [CrossRef] [PubMed]
  203. Islam, T.; Haque, M.A.; Barai, H.R.; Istiaq, A.; Kim, J.J. Antibiotic Resistance in Plant Pathogenic Bacteria: Recent Data and Environmental Impact of Unchecked Use and the Potential of Biocontrol Agents as an Eco-Friendly Alternative. Plants 2024, 13, 1135. [Google Scholar] [CrossRef] [PubMed]
  204. Islam, T.; Tamanna, N.T.; Sagor, M.S.; Zaki, R.M.; Rabbee, M.F.; Lackner, M. Antimicrobial Peptides: A Promising Solution to the Rising Threat of Antibiotic Resistance. Pharmaceutics 2024, 16, 1542. [Google Scholar] [CrossRef]
  205. Islam, T.; Danishuddin Tamanna, N.T.; Matin, M.N.; Barai, H.R.; Haque, M.A. Resistance Mechanisms of Plant Pathogenic Fungi to Fungicide, Environmental Impacts of Fungicides, and Sustainable Solutions. Plants 2024, 13, 2737. [Google Scholar] [CrossRef]
  206. Halkjær, S.I.; Danielsen, M.R.; de Knegt, V.E.; Andersen, L.O.; Stensvold, C.R.; Nielsen, H.V.; Mirsepasi-Lauridsen, H.C.; Krogfelt, K.A.; Cortes, D.; Petersen, A.M. Multi-strain probiotics during pregnancy in women with obesity influence infant gut microbiome development: Results from a randomized, double-blind placebo-controlled study. Gut Microbes 2024, 16, 2337968. [Google Scholar] [CrossRef]
  207. Ma, G.; Yan, H.; Tye, K.D.; Tang, X.; Luo, H.; Li, Z.; Xiao, X. Effect of probiotic administration during pregnancy on the functional diversity of the gut microbiota in healthy pregnant women. Microbiol. Spectr. 2024, 12, 6. [Google Scholar] [CrossRef]
  208. Eguren, C.; Navarro-Blasco, A.; Corral-Forteza, M.; Reolid-Pérez, A.; Setó-Torrent, N.; García-Navarro, A.; Prieto-Merino, D.; Núñez-Delegido, E.; Sánchez-Pellicer, P.; Navarro-López, V. A Randomized Clinical Trial to Evaluate the Efficacy of an Oral Probiotic in Acne Vulgaris. Acta Derm. Venereol. 2024, 104, adv33206. [Google Scholar] [CrossRef]
  209. Huang, F.; Li, S.; Chen, W.; Han, Y.; Yao, Y.; Yang, L.; Li, Q.; Xiao, Q.; Wei, J.; Liu, Z.; et al. Postoperative Probiotics Administration Attenuates Gastrointestinal Complications and Gut Microbiota Dysbiosis Caused by Chemotherapy in Colorectal Cancer Patients. Nutrients 2023, 15, 356. [Google Scholar] [CrossRef]
  210. Martin, F.P.; Cominetti, O.; Berger, B.; Combremont, S.; Marquis, J.; Xie, G.; Jia, W.; Pinto-Sanchez, M.I.; Bercik, P.; Bergonzelli, G. Metabolome-associated psychological comorbidities improvement in irritable bowel syndrome patients receiving a probiotic. Gut Microbes 2024, 16, 2347715. [Google Scholar] [CrossRef]
  211. Wei, S.; Bahl, M.I.; Baunwall, S.M.D.; Dahlerup, J.F.; Hvas, C.L.; Licht, T.R. Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection. Gut Microbes 2022, 14, 2084306. [Google Scholar] [CrossRef]
  212. Wu, Z.; Zhang, B.; Chen, F.; Xia, R.; Zhu, D.; Chen, B.; Lin, A.; Zheng, C.; Hou, D.; Li, X.; et al. Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: A randomized, controlled, prospective study. Front. Cell Infect. Microbiol. 2023, 12, 1089991. [Google Scholar] [CrossRef]
  213. Chen, Q.; Fan, Y.; Zhang, B.; Yan, C.; Zhang, Q.; Ke, Y.; Chen, Z.; Wang, L.; Shi, H.; Hu, Y.; et al. Capsulized Fecal Microbiota Transplantation Induces Remission in Patients with Ulcerative Colitis by Gut Microbial Colonization and Metabolite Regulation. Microbiol. Spectr. 2023, 11, e0415222. [Google Scholar] [CrossRef] [PubMed]
  214. Wu, L.; Zhou, J.; Zhou, A.; Lei, Y.; Tang, L.; Hu, S.; Wang, S.; Xiao, X.; Chen, Q.; Tu, D.; et al. Lactobacillus acidophilus ameliorates cholestatic liver injury through inhibiting bile acid synthesis and promoting bile acid excretion. Gut Microbes 2024, 16, 2390176. [Google Scholar] [CrossRef] [PubMed]
  215. Srivastava, S.; Basak, U.; Naghibi, M.; Vijayakumar, V.; Parihar, R.; Patel, J.; Jadon, P.S.; Pandit, A.; Dargad, R.R.; Khanna, S.; et al. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome. Gut Microbes 2024, 16, 2338322. [Google Scholar] [CrossRef] [PubMed]
  216. Mutoh, N.; Moriya, M.; Xu, C.; Kato, K.; Arai, S.; Iwabuchi, N.; Tanaka, M.; Jinghua, Y.; Itamura, R.; Sakatani, K.; et al. Bifidobacterium breve M-16V regulates the autonomic nervous system via the intestinal environment: A double-blind, placebo-controlled study. Behav. Brain Res. 2024, 460, 114820. [Google Scholar] [CrossRef]
  217. Niu, Y.; Li, J.; Qian, H.; Liang, C.; Shi, X.; Bu, S. Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication of Helicobacter pylori: A randomized, double-blind, placebo-controlled trial. Front. Immunol. 2024, 15, 1450414. [Google Scholar] [CrossRef]
  218. Zuppi, M.; Vatanen, T.; Wilson, B.C.; Golovina, E.; Portlock, T.; Cutfield, W.S.; Vickers, M.H.; O’sullivan, J.M. Fecal microbiota transplantation alters gut phage communities in a clinical trial for obesity. Microbiome 2024, 12, 122. [Google Scholar] [CrossRef]
  219. Gurbatri, C.R.; Radford, G.A.; Vrbanac, L.; Im, J.; Thomas, E.M.; Coker, C.; Taylor, S.R.; Jang, Y.; Sivan, A.; Rhee, K.; et al. Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia. Nat. Commun. 2024, 15, 646. [Google Scholar] [CrossRef]
  220. Zhang, F.; Cui, B.; He, X.; Nie, Y.; Wu, K.; Fan, D.; FMT-standardization Study Group. Microbiota transplantation: Concept, methodology and strategy for its modernization. Protein Cell 2018, 9, 462–473. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.